The Indian pharmaceutical market delivered a moderate rise in revenue of 5.2% year-on-year in May as volume declined 3.3%.
The pharma market reported a healthy growth at an average of 9% year-on-year between December 2023 and April 2024. There was lower growth in therapies like gastrointestinal, anti-diabetic, vitamins, pain management, derma, central nervous system and gynaecology, according to the All India Organisation of Chemists and Druggists.
Anti-infectives and respiratory therapy delivered double-digit growth. Price and new launches drove the overall pharma market performance in India in May, rising 6% and 2.6% respectively.
India Ratings and Research expects the IPM growth to be at 8–9% the current financial year against 6.5% in fiscal 2024 and 9.9% in fiscal 2023, Krishnanath Munde, associate director at India Ratings, told NDTV Profit.
Key Highlights
Volume declined 3.3%, as against 0.8% in May 2023.
Price growth of 6% in May 2024.
New launches increased 2.6%, as compared with 2.9% in May 2023.
Sales Highlights
There was lower growth in therapies like gastrointestinal, which grew 4.7%. Anti-diabetic grew 4.8% and derma grew 4.2%.
Anti-infectives and respiratory therapy delivered double-digit growth.
MAT Performance
The moving annual total—or the 12-month rolling sales of overall pharma products—increased 7.3% in May.
Company Performance
Faster Than Industry
Alembic Pharma and FDC India outperformed the market. This was followed by Alkem Laboratories, Torrent Pharmaceuticals and Natco Pharma which grew 11.7% and 11.6% and 11.1% respectively.
Cipla grew 9.3%, followed by Glenmark Pharmaceuticals, which grew 8.9%. Indoco Remedies and Sanofi India grew 6.5% and 6.4% respectively. Ipca Laboratories grew 7% while Lupin grew 6.1%
Slower Than Industry
Pfizer India, Ajanta Pharma and Abbott India had a negative growth of 5.1%, 1.3% and 0.1%.
Dr Reddy's Laboratories grew 2.1%, while GlaxoSmithKline Pharmaceuticals grew 2.7% underperforming the market. Eric Lifesciences and JB Chemicals grew 1.7% and 0.5% respectively.
Sun Pharmaceuticals Industries grew in line with market at 5.1%
RECOMMENDED FOR YOU
Sensex 2025-End Target To Be Hiked? HSBC's Herald Van Der Linde Bullish On India's Growth Story—Top Picks
Aug 25, 2025
Nifty To Hit 30,000 In 2026? Behind JPMorgan's Bull Case—Key Sectors And Stocks To Watch
Aug 19, 2025
Indian Tablet PC Market Grows 20% In Q2 FY25; Apple Leads With 30% Share: Cybermedia
Aug 16, 2025
Torrent Pharma Q1 Review: Citi Hikes Target Price — Here's Why
Jul 29, 2025
POPULAR